PDF file, 3170KB, (A) Schematic representation of the genomic region containing fig and ros1. Probes set 1 derived from ros1 (orange) and the deleted region (green). Probe set 2 derived from ros1 (orange) and fig (green). (B,C) Yellow arrows point to split signals indicative of balanced translocation in the HCC78 cell line and white arrows point to intact chromosome. (D,F) In both U-118 MG and tumor ID 749 only the ros1 (orange) probe anneals and the deleted region (green probe) does not. (E,G) ros1 (orange) and fig (green) probes overlap indicating fig-ros1 fusion. (H)

Supplementary Figures 1-5 from Tumor-Secreted Vascular Endothelial Growth Factor-C Is Necessary for Prostate Cancer Lymphangiogenesis, but Lymphangiogenesis Is Unnecessary for Lymph Node Metastasis

XLSX file, 43KB, RT-PCR Results for FFPE ROS positive tumors.

PDF file - 45K, ALK and FN1-ALK tumors are sensitive to TAE684 treatment

PDF file - 129K, A novel fusion: FN1-ALK

XLS file - 68K, Phospho-tyrosine Peptides of Tyrosine Kinases Identified by LC-MS/MS in Ovarian Tissues

Supplementary Figure Legends

PDF file, 5111KB, (A) A representative image of ALK break apart FISH (yellow arrows point to break apart). Images of ALK /L858R positive lung adenocarcinoma stained with (B) ALK D5F3, (C) total EGFR, (D) EGFR A746-E750del and (E) EGFR L858R antibodies.

(A) A representative image of ALK break apart FISH (yellow arrows point to break apart). Images of ALK /L858R positive lung adenocarcinoma stained with (B) ALK D5F3, (C) total EGFR, (D) EGFR A746-E750del and (E) EGFR L858R antibodies.

<p>PDF file - 50K, Hyperphosphorylation of signaling molecules in serous carcinomas bearing ALK</p>

XLS file - 31K, Patient Diagnostic Information

Supplementary Data from Mutation-Specific Antibodies for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer

CCR Translation for This Article from Analysis of Receptor Tyrosine Kinase ROS1-Positive Tumors in Non–Small Cell Lung Cancer: Identification of a FIG-ROS1 Fusion

Supplemental Table I RT-PCR Results for FFPE ROS1 positive tumors

Supplemental Fig 1. Epithelial and stromal PD-L1 expression. Supplemental Fig 2. Validation of specificity of PD-L1 antibody used in this study. Supplemental Fig 3. Correlation with PD-L1 expression and pCR in patient subsets. Supplemental Fig 4. Joinpoint analysis of PD-L1 quantitative scores in the tumor mask (A) and stromal compartment (B). Supplemental Fig 5. Contingency tables of PD-L1 in the epithelium (A) and stroma (B) dichotomized by Joinpoint into low and high with pCR.

XLS file - 40K, Abundance of phospho-peptides corresponding to specific signaling molecules in selective serous carcinoma patients

PDF file - 175K, Activation and ALK inhibitor sensitivity of down stream molecules in 293T cells expressing ALK and FN1-ALK

<p>PDF file - 127K, Detection of two common ALK peptides containing phospho-Y1507 in 4 patients</p>

Supplemental Table 1. Exclusion of Ki67 from Table 4 shows that both stromal and epithelial PD-L1 expressions are highly significant in multivariate analysis.